News | December 28, 2023
Elpiscience and Astellas collaborate for novel bispecific macrophage engager
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
NEIAFMR to be developed as the national hub for folk medicine
The plant is yet to start commercial operations
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
His most recent stint was with Danone India as its Managing Director
10+ emerging markets, Japan & ANZ transition in final phase
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
Subscribe To Our Newsletter & Stay Updated
